Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Active, not recruiting · NCT04988386 · Registry updated 2025-10-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants | Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, proteostasis deficiencies | Active, not recruiting | Phase 3 | 2025-10-14 | NCT04988386 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eidos Therapeutics, a BridgeBio company | 6 |
72 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.